A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Inclusion Criteria:

- Confirmed relapsed/refractory lymphoid malignancies

- Previously treated with at least 2 therapeutic regimens

- ECOG performance < 2.

- Life expectancy of at least 3 months

- Adequate renal function

- Adequate hematologic status

- Adequate liver function

- Transfusion independent

Exclusion Criteria:

- Received other therapy (biological or drug) to treat cancer within 4 weeks prior to
starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer
treatment toxicity

- The use of systemic corticosteroids within 1 week of starting treatment with HGS1029

- Evidence of active bacterial, viral or fungal infection within 2 weeks before
starting treatment with HGS1029

- Known HIV infection

- Positive for hepatitis B surface antigen or positive hepatitis C antibody

- Grade 2 or greater neuropathy

- Pregnant female or nursing mother

- Males or females who do not agree to use effective contraception during the study and
through at least 30 days after the last dose of HGS1029